CVS Health (CVS)
(Delayed Data from NYSE)
$67.77 USD
-0.73 (-1.07%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $67.71 -0.06 (-0.09%) 6:26 PM ET
4-Sell of 5 4
B Value F Growth D Momentum D VGM
Price, Consensus and EPS Surprise
CVS 67.77 -0.73(-1.07%)
Will CVS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CVS
Earnings Preview: CVS Health (CVS) Q1 Earnings Expected to Decline
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
CVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
CVS Health (CVS) Rises As Market Takes a Dip: Key Facts
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
Other News for CVS
CVS Health invests $19.2 million in affordable housing in Arvada, Colorado
Wall Street Analysts Are Bullish on Top Healthcare Picks
Baum Family Investments Embarks on Triple Net Lease Strategy with $250 Million Acquisition Goal
Looking Into CVS Health's Recent Short Interest
FTC looking to accelerate inquiry into prescription-drug middlemen, chair says